Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma: Advanced Disease

Join Jeffrey M. Farma, MD and Anthony J. Olszanski, MD from Fox Chase Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to advanced melanoma.

The continuing development of novel immunotherapeutic and targeted agents for advanced melanoma has propelled the field to an exciting era. Immunotherapies harness the body’s natural immune system and have the potential to achieve a durable response in patients with metastatic melanoma. Treatment decisions for advanced melanoma are becoming increasingly complicated with the explosion of new agents that demonstrated survival benefits. As each agent requires careful initial selection as well as follow-up for specific side effects, clinicians need to be able to clearly discern and explain which agent or combination will best fit an individual patient based on tumor burden, symptoms, mutation status, and overall health.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Interpret data on immunotherapeutic agents against the PD-1 immune checkpoint in patients with advanced melanoma
  • Outline the evidence that supports combined BRAF-MEK inhibition compared to single-agent targeted therapy
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.77 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
10/30/2015
Course expires: 
10/30/2016
Cost:
$0.00

Jeffrey M. Farma, MD
Fox Chase Cancer Center

Anthony J. Olszanski, MD
Fox Chase Cancer Center

Available Credit

  • 0.75 Participation
  • 0.77 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Accreditation Period

Course opens: 
10/30/2015
Course expires: 
10/30/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • For Windows: JavaScript and cookies enabled, Active X enabled and unblocked for Microsoft Internet Explorer, Java 6.0 or above
  • For Mac: JavaScript and cookies enabled, Plug-ins enabled in Safari, Java 6.0 or above
  • Adobe Reader or other PDF reader software for certificate viewing/printing